{"organizations": [], "uuid": "d3bc86075a9d555471b6943ed54b7a85bb13d8e0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000551/device/rss", "section_title": "California", "url": "https://www.cnbc.com/2018/02/27/the-associated-press-genmark-diagnostics-reports-4q-loss.html", "country": "US", "domain_rank": 767, "title": "GenMark Diagnostics reports 4Q loss", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-28T02:11:00.000+02:00", "replies_count": 0, "uuid": "d3bc86075a9d555471b6943ed54b7a85bb13d8e0"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/02/27/the-associated-press-genmark-diagnostics-reports-4q-loss.html", "ord_in_thread": 0, "title": "GenMark Diagnostics reports 4Q loss", "locations": [], "entities": {"persons": [], "locations": [{"name": "carlsbad", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}, {"name": "carlsbad", "sentiment": "none"}], "organizations": [{"name": "genmark diagnostics inc.", "sentiment": "negative"}, {"name": "genmark diagnostics", "sentiment": "negative"}, {"name": "ap", "sentiment": "negative"}, {"name": "zacks investment research", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "CARLSBAD, Calif. (AP) _ GenMark Diagnostics Inc. (GNMK) on Tuesday reported a loss of $14.5 million in its fourth quarter.\nThe Carlsbad, California-based company said it had a loss of 26 cents per share.\nThe results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 24 cents per share.\nThe molecular diagnostics company posted revenue of $16 million in the period, which beat Street forecasts. Three analysts surveyed by Zacks expected $15.8 million.\nFor the year, the company reported that its loss widened to $61.9 million, or $1.21 per share. Revenue was reported as $52.5 million.\nGenMark Diagnostics expects full-year revenue in the range of $68 million to $72 million.\nIn the final minutes of trading on Tuesday, the company's shares hit $4.89. A year ago, they were trading at $11.59.\nThis story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on GNMK at https://www.zacks.com/ap/GNMK", "external_links": [], "published": "2018-02-28T02:11:00.000+02:00", "crawled": "2018-02-28T03:00:04.010+02:00", "highlightTitle": ""}